A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation

Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation

(2021) Ruth Van Daele et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

(2021) Johan A Maertens et al.   LANCET

Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19—Where Are We Now?

(2021) Zbigniew Putowski et al.   International Journal of Environmental Research and Public Health

Voriconazole Sequestration During Extracorporeal Membrane Oxygenation for Invasive Lung Aspergillosis

(2021) Alexandre Mathieu et al.   ASAIO JOURNAL

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study

(2020) Camille Mané et al.   Journal of Translational Medicine

Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy

(2020) Hao Li et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Oxygenator impact on voriconazole in extracorporeal membrane oxygenation circuits

(2020) Jeffrey J Cies et al.   PERFUSION-UK

Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations

(2020) Christoph Zurl et al.   Journal of Fungi

COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment

(2020) Amir Arastehfar et al.   Journal of Fungi

Sequestration of Voriconazole and Vancomycin Into Contemporary Extracorporeal Membrane Oxygenation Circuits: An in vitro Study

(2020) Genny Raffaeli et al.   Frontiers in Pediatrics

Decreasing voriconazole requirement in a patient after extracorporeal membrane oxygenation discontinuation: A case report

(2020) Eric L. Peterson et al.   Transplant Infectious Disease

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

(2019) Jesus Ruiz et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism

(2019) Josefine Schulz et al.   DRUG METABOLISM REVIEWS

Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation

(2019) Yanjun Zhao et al.   PHARMACOTHERAPY

Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases

(2018) Thomas Kaindl et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Invasive mould infections in the ICU setting: complexities and solutions

(2017) Matteo Bassetti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients

(2017) J. Hahn et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study

(2017) Whitley M. Yi et al.   Annals of Clinical Microbiology and Antimicrobials

Voriconazole concentration monitoring at an academic medical center

(2016) J. C. Sebaaly et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

Fungal infections in the ICU

(2015) Gennaro De Pascale et al.   Current Opinion in Critical Care

Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies

(2013) Martin Hoenigl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: critical appraisal

(2013) S. Leroux et al.   CLINICAL MICROBIOLOGY AND INFECTION

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

(2013) H. R. Ashbee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study

(2012) Joost Wauters et al.   INTENSIVE CARE MEDICINE

Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study

(2010) Pavlos Myrianthefs et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation

(2009) I. Spriet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Pharmacokinetic Profile of Voriconazole During Continuous High-volume Venovenous Hemofiltration in a Critically Ill Patient

(2009) Hervé Quintard et al.   THERAPEUTIC DRUG MONITORING

Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation

(2008) Stéphanie Ruiz et al.   INTENSIVE CARE MEDICINE

Therapeutic Drug Monitoring of Voriconazole in a Child With Invasive Aspergillosis Requiring Extracorporeal Membrane Oxygenation

(2008) Roger J M Brüggemann et al.   THERAPEUTIC DRUG MONITORING